NCT01826474终止1 期
A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 6
- 主要终点
- Change from baseline in 6 minute walk test
研究概览
简要总结
The purpose of the study is to see whether PRO045 is safe and effective to use as medication for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 45 in the DNA for the dystrophin protein.
详细描述
A phase IIb, open-label, multiple-dose study. The study consists of two phases; a dose escalation phase (with subsequent dose-titration) and a 48-week treatment phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 18 Years（Child, Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Duchenne muscular dystrophy resulting from a mutation correctable by treatment with PRO045 confirmed by a state-of-the-art DNA diagnostic technique covering all DMD gene exons, including but not limited to MLPA (Multiplex Ligation-dependent Probe Amplification), CGH (Comparative Genomic Hybridisation), SCAIP (Single Condition Amplification/Internal Primer) or HRMCA (High-Resolution Melting Curve Analysis), and correctable by PRO045-induced DMD exon 45 skipping in cultured skin-derived myo-converted fibroblasts.
- •Ambulant boys aged at least 5 years on the day of first dosing able to walk for at least 230 meters in the 6 minute walking distance (6MWD) test at first screening visit and also at the baseline visit. In addition, 2 of the 3 pre-treatment 6MWD tests (screen 1, screen 2, baseline) must be within +/-30 metres of each other prior to first PRO045 administration.
- •Adequate quality for biopsy (confirmed with MRI) of the lateral head of the gastrocnemius muscle. An alternative muscle may be considered for biopsy but only following discussion between the Principal Investigator and the Prosensa Medical Monitor.
- •Life expectancy of at least 3 years after inclusion in the study.
- •Glucocorticosteroid use which is stable for at least 3 months prior to first PRO045 administration. Subjects must have been receiving glucocorticosteroids for at least 6 months prior to the first PRO045 administration.
- •Willing and able to adhere to the study visit schedule and other protocol requirements.
- •Written informed consent signed (by parent(s)/legal guardian and/or the subject, according to the local regulations).
- •In France, a subject will be eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category.
排除标准
- •Known presence of dystrophin in ≥5% of fibres in a pre-study diagnostic muscle biopsy (i.e. historic muscle biopsy taken prior to written informed consent for this study).
- •Current or history of liver disease or impairment.
- •Current or history of renal disease or impairment.
- •At least two aPTT above ULN within the last month.
- •Screening platelet count below the lower limit of normal (LLN).
- •Acute illness within 4 weeks prior to first dose of PRO045 which may interfere with the study assessments.
- •Severe mental retardation or behavioural problems which in the opinion of the investigator prohibits participation in this study.
- •Severe cardiomyopathy which in the opinion of the investigator prohibits participation in this study. If a subject has a left ventricular ejection fraction <45% at screening, the investigator should discuss inclusion of the subject with the Medical Monitor.
- •Expected need for daytime mechanical ventilation within the next year.
- •Use of anticoagulants, antithrombotics or antiplatelet agents.
- •Use of idebenone or other forms of coenzyme Q10 within 1 month prior to the start of the screening for the study.
- •Use of nutritional or herbal supplements which, in the opinion of the investigator, may influence muscle performance, within 1 month of the study.
- •Use of any other investigational product or participation in another trial with an investigational product, within 6 months prior to the start of the screening for the study.
研究组 & 干预措施
PRO045, cohort 5
Experimental
9.0 mg/kg until move to 48 week treatment phase
干预措施: PRO045, 9.0 mg/kg/week (Drug)
PRO045, cohort 1
Experimental
0.15 mg/kg until dose-titration
干预措施: PRO045, 0.15 mg/kg/week (Drug)
PRO045, cohort 2
Experimental
1.0 mg/kg until dose-titration
干预措施: PRO045, 1.0 mg/kg/week (Drug)
PRO045, cohort 3
Experimental
3.0 mg/kg until dose-titration
干预措施: PRO045, 3.0 mg/kg/week (Drug)
PRO045, cohort 4
Experimental
6.0 mg/kg until dose-titration
干预措施: PRO045, 6.0 mg/kg/week (Drug)
PRO045, cohort 6
Experimental
48 week treatment phase
干预措施: PRO045, selected dose (Drug)
结局指标
主要结局
Change from baseline in 6 minute walk test
时间窗: after 48 weeks of treatment phase
次要结局
- Muscle function(after 48 weeks of treatment phase)
- Performance of upper limb(after 48 weeks of treatment phase)
- Functional outcomes questionnaire(after 48 weeks of treatment)
- Muscle strength(after 48 weeks treatment phase)
- Safety(after 48 weeks of treatment phase)
研究者
研究点 (6)
Loading locations...
相似试验
终止
2 期
Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNCT02329769BioMarin Pharmaceutical15
已完成
1 期
Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNCT01037309BioMarin Pharmaceutical18
终止
1 期
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNCT01957059BioMarin Pharmaceutical9
已完成
2 期
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.Non Small Cell Lung CancerNCT00160043Bayer112
终止
2 期
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaNCT03254927Celldex Therapeutics30